Loss of IGF2 imprinting:: A potential marker of colorectal cancer risk
Loss of IGF2 imprinting:: A potential marker of colorectal cancer risk
复制标题
DOI：
10.1126/science.1080902
复制
发表时间：
2003-03-14
期刊：
影响因子：
56.9
通讯作者：
Feinberg, AP
中科院分区：
文献类型：
--
作者：
Cui, HM;Cruz-Correa, M;Feinberg, AP
印迹丢失(LOI)是一种影响胰岛素样生长因子II基因(IGF2)的表观遗传学改变，在大约30%的结直肠癌(CRC)患者的正常结肠粘膜中发现，但在健康人中只有10%。在一项初步研究中，我们在结肠镜检查诊所评估了172名患者，以调查LOI作为结直肠癌风险标志物的实用性。有阳性家族史的患者淋巴细胞LOI调整后的优势比为5.15[95%可信区间(95%CI)，1.7~16.96；概率P=0.002]，腺瘤患者为3.46(95%CI，1.14~11.37，P=0.026)，结直肠癌患者为21.7(95%CI，3.48~153.6，P=0.0005)。LOI可以通过基于DNA的血液测试来检测，它可能是一个有价值的预测个体患CRC风险的标志物。
Loss of imprinting (LOI), an epigenetic alteration affecting the insulin-like growth factor II gene (IGF2), is found in normal colonic mucosa of about 30% of colorectal cancer (CRC) patients, but it is found in only 10% of healthy individuals. In a pilot study to investigate the utility of LOI as a marker of CRC risk, we evaluated 172 patients at a colonoscopy clinic. The adjusted odds ratio for LOI in lymphocytes was 5.15 for patients with a positive family history [95% confidence interval (95% CI), 1.70 to 16.96; probability P = 0.002], 3.46 for patients with adenomas (95% CI, 1.14 to 11.37; P = 0.026), and 21.7 for patients with CRC (95% CI, 3.48 to 153.6; P = 0.0005). LOI can be assayed with a DNA-based blood test, and it may be a valuable predictive marker of an individual's risk for CRC.